On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


MetAlert, Inc. (MLRT) – Developing New and Practical GPS Tracking and Other Health Tech Solutions for Real-World Caregivers and Businesses

  • MetAlert, a developer of personal protective medical equipment and supplies, owes much of its growth to acting on feedback from real-world caregivers who use its products for the monitoring and tracking of vulnerable patients
  • This connection with caregivers has yielded advanced products such as the award-winning, multi-patented GPS SmartSole, Invisabelt, Take-Along Tracker, and Rover Tracker, among others
  • Attention to consumers has also led to its line of hearing aids, such as its flagship Hear IQ 4 rechargeable, app-controlled hearing aid, and its RoomMate wall-mounted 3D sensors for looking after patients without intruding on their personal space

MetAlert (OTC: MLRT), a developer of personal protective medical equipment and supplies and a pioneer of wearable GPS, human, and asset tracking systems, pays constant and close consideration to feedback from real-world caregivers, and the needs of those who use its products. With over 20 years of experience and an extensive patent portfolio, the company is continually developing viable solutions to individuals afflicted with Alzheimer’s, dementia, and autism (“ADA”), making it one of the few companies that offer practical solutions specific to this group of individuals.

MetAlert is driven by the need to engineer solutions to everyday challenges while maintaining a non-invasive approach to the carrier. This approach has yielded products such as the award-winning, multi-patented GPS SmartSole, the world’s first hidden wearable GPS tracking solution, as well as Invisabelt, Take-Along Tracker, and Rover Tracker, among others. In addition, MetAlert’s Monitoring Portal, accessible via web login, allows caregivers to track those possessing these devices, affording them better care (https://ibn.fm/KY87Z).

General quality-of-life improvements are integral to MetAlert’s overall approach to business. This is evidenced by its line of hearing aids, ranging from its flagship Hear IQ 4 rechargeable, app-controlled hearing aid to its RoomMate wall-mounted 3D sensors for looking after patients without intruding on their personal space. Focusing on such a unique market has allowed the company to grow its market share and reach. It is expected to grow even further in the new year, especially given its recent strategic acquisition of TrakTec LLC.

“It is really about increasing the quality of life, the longevity or people that are challenged,” noted Patrick Bertagna, MetAlert’s CEO (https://ibn.fm/dtMj4).

According to PatSnap, in 2019, over 722 million wearable devices were in use globally, with the number expected to hit one billion by the end of 2023. This, coupled with the fact that non-communicable diseases claim over 41 million lives each year and about 17 million annually before they reach the age of 70, presents a growing need for robust, practical, and effective patient monitoring systems, a need which MetAlert is looking to satisfy (https://ibn.fm/e12Ad). In addition, the growing attention to lifestyle wellness factors creates a market for the company’s products. Its unique approach to their development and marketing sets it apart from its peers, allowing it to impact even more lives as time progresses.

Having had an incredible start to the new year, MetAlert remains committed to growing its platform and range of products and services. It also remains committed to offering solutions with real-world caregivers and businesses in mind, providing resolutions to everyday challenges, and bringing quality-of-life improvements to persons living with ADA.

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

From Our Blog

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

March 18, 2024

With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to advance its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization. To boost […]

Rotate your device 90° to view site.